Diary - News
All news Alaxia Announces $1.7 Million Award from Cystic Fibrosis Foundation Therapeutics to Start Clinical Development of ALX-009 in Patients
Alaxia SAS announced today an agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), Bethesda, Md., to help support the first-in-patient clinical study of its inhaled antimicrobial drug candidate ALX-009.
By delivering two key endogenous antimicrobial substances directly to the lung, ALX-009 is intended to compensate for the defective innate lung defense system of people with cystic fibrosis (CF).
ALX-009 already demonstrated in vitro its therapeutic potential against a wide range of bacterial species infecting CF lungs and particularly against clinical isolates with natural or acquired multi-drug resistance.
ALX-009 efficacy is not altered by complex structures such as biofilm or sputum present in CF lungs. ALX-009 has the potential to limit emergence of resistance and induction of cross-resistance to available antibiotics thanks to its innovative mode of action. A Phase I clinical trial involving healthy volunteers and CF patients is ongoing.
Lire le Communiqué de presse
